Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials
Abstract Microtubule associated protein tau (MAPT) is a naturally occurring protein that plays a significant role in stabilizing microtubules, which are essential for the transport of nutrients and other materials within neurons. In tauopathies, tau protein assembles into mis-folded multimers rangin...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | Alzheimer’s Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13195-025-01775-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849470003996262400 |
|---|---|
| author | Glenn A. Harris Lauren R. Hirschfeld M. Isabel Gonzalez Martyn C. Pritchard Patrick C. May |
| author_facet | Glenn A. Harris Lauren R. Hirschfeld M. Isabel Gonzalez Martyn C. Pritchard Patrick C. May |
| author_sort | Glenn A. Harris |
| collection | DOAJ |
| description | Abstract Microtubule associated protein tau (MAPT) is a naturally occurring protein that plays a significant role in stabilizing microtubules, which are essential for the transport of nutrients and other materials within neurons. In tauopathies, tau protein assembles into mis-folded multimers ranging from soluble oligomers to insoluble aggregates, known as neurofibrillary tangles, neuropil threads and are components of neuritic plaques. These abnormal tau assemblies collectively are thought to disrupt the normal function of neurons and lead to their death. Tauopathies are a leading cause of neurodegeneration, and there are no approved disease modifying therapies targeting the tau pathology for any tauopathy. This review is a two-year update to an initial review of preclinical, clinical, and recently discontinued therapeutic programs in development focused on ameliorating tau pathology. This review outlines the landscape of therapeutic drugs indexed through January 1, 2025. Currently, there are 170 drugs monitored in the pipeline, one less than in the previous period. In the clinic, there are five candidates in phase 3 trials, 15 in phase 2 trials, and 12 in phase 1 trials. In total, there are four less candidates in clinical trials during this review period than the last. New to this review is the inclusion of the clinical development of tau positron emission tomography (PET) ligands which undergo regulatory oversite. In addition to the one FDA-approved tau PET ligand Tauvid™ (flortaucipir), there are six additional tau PET ligands currently in active clinical trials. |
| format | Article |
| id | doaj-art-426974a881214259a67d66a5873b95fa |
| institution | Kabale University |
| issn | 1758-9193 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Alzheimer’s Research & Therapy |
| spelling | doaj-art-426974a881214259a67d66a5873b95fa2025-08-20T03:25:16ZengBMCAlzheimer’s Research & Therapy1758-91932025-06-0117112210.1186/s13195-025-01775-xRevisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trialsGlenn A. Harris0Lauren R. Hirschfeld1M. Isabel Gonzalez2Martyn C. Pritchard3Patrick C. May4Rainwater Charitable FoundationRainwater Charitable FoundationDrug Discovery and Development Consultants LtdDrug Discovery and Development Consultants LtdADvantage Neuroscience Consulting LLCAbstract Microtubule associated protein tau (MAPT) is a naturally occurring protein that plays a significant role in stabilizing microtubules, which are essential for the transport of nutrients and other materials within neurons. In tauopathies, tau protein assembles into mis-folded multimers ranging from soluble oligomers to insoluble aggregates, known as neurofibrillary tangles, neuropil threads and are components of neuritic plaques. These abnormal tau assemblies collectively are thought to disrupt the normal function of neurons and lead to their death. Tauopathies are a leading cause of neurodegeneration, and there are no approved disease modifying therapies targeting the tau pathology for any tauopathy. This review is a two-year update to an initial review of preclinical, clinical, and recently discontinued therapeutic programs in development focused on ameliorating tau pathology. This review outlines the landscape of therapeutic drugs indexed through January 1, 2025. Currently, there are 170 drugs monitored in the pipeline, one less than in the previous period. In the clinic, there are five candidates in phase 3 trials, 15 in phase 2 trials, and 12 in phase 1 trials. In total, there are four less candidates in clinical trials during this review period than the last. New to this review is the inclusion of the clinical development of tau positron emission tomography (PET) ligands which undergo regulatory oversite. In addition to the one FDA-approved tau PET ligand Tauvid™ (flortaucipir), there are six additional tau PET ligands currently in active clinical trials.https://doi.org/10.1186/s13195-025-01775-xAlzheimer's diseaseDrug developmentFrontotemporal dementiaProgressive supranuclear palsyCorticobasal degenerationMAPT |
| spellingShingle | Glenn A. Harris Lauren R. Hirschfeld M. Isabel Gonzalez Martyn C. Pritchard Patrick C. May Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials Alzheimer’s Research & Therapy Alzheimer's disease Drug development Frontotemporal dementia Progressive supranuclear palsy Corticobasal degeneration MAPT |
| title | Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials |
| title_full | Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials |
| title_fullStr | Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials |
| title_full_unstemmed | Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials |
| title_short | Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials |
| title_sort | revisiting the therapeutic landscape of tauopathies assessing the current pipeline and clinical trials |
| topic | Alzheimer's disease Drug development Frontotemporal dementia Progressive supranuclear palsy Corticobasal degeneration MAPT |
| url | https://doi.org/10.1186/s13195-025-01775-x |
| work_keys_str_mv | AT glennaharris revisitingthetherapeuticlandscapeoftauopathiesassessingthecurrentpipelineandclinicaltrials AT laurenrhirschfeld revisitingthetherapeuticlandscapeoftauopathiesassessingthecurrentpipelineandclinicaltrials AT misabelgonzalez revisitingthetherapeuticlandscapeoftauopathiesassessingthecurrentpipelineandclinicaltrials AT martyncpritchard revisitingthetherapeuticlandscapeoftauopathiesassessingthecurrentpipelineandclinicaltrials AT patrickcmay revisitingthetherapeuticlandscapeoftauopathiesassessingthecurrentpipelineandclinicaltrials |